UA122719C2 - Лікування внутрішньопечінкових холестатичних захворювань - Google Patents

Лікування внутрішньопечінкових холестатичних захворювань Download PDF

Info

Publication number
UA122719C2
UA122719C2 UAA201811776A UAA201811776A UA122719C2 UA 122719 C2 UA122719 C2 UA 122719C2 UA A201811776 A UAA201811776 A UA A201811776A UA A201811776 A UAA201811776 A UA A201811776A UA 122719 C2 UA122719 C2 UA 122719C2
Authority
UA
Ukraine
Prior art keywords
seladelpar
intrahepatic
compound
intrahepatic cholestatic
disease
Prior art date
Application number
UAA201811776A
Other languages
English (en)
Ukrainian (uk)
Inventor
Пол Буд
Чарлз А. МакВертер
Original Assignee
Сімабей Терапьютікс, Інк.
Симабэй Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сімабей Терапьютікс, Інк., Симабэй Терапьютикс, Инк. filed Critical Сімабей Терапьютікс, Інк.
Publication of UA122719C2 publication Critical patent/UA122719C2/uk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UAA201811776A 2016-05-31 2017-04-26 Лікування внутрішньопечінкових холестатичних захворювань UA122719C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662343688P 2016-05-31 2016-05-31
PCT/US2017/029620 WO2017209865A1 (en) 2016-05-31 2017-04-26 Treatment of intrahepatic cholestatic diseases

Publications (1)

Publication Number Publication Date
UA122719C2 true UA122719C2 (uk) 2020-12-28

Family

ID=58699276

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201811776A UA122719C2 (uk) 2016-05-31 2017-04-26 Лікування внутрішньопечінкових холестатичних захворювань

Country Status (27)

Country Link
US (5) US10272058B2 (https=)
EP (1) EP3463328B1 (https=)
JP (1) JP7079735B2 (https=)
KR (1) KR102408288B1 (https=)
CN (2) CN109195594A (https=)
AU (1) AU2017274293B2 (https=)
BR (1) BR112018074147A2 (https=)
CA (1) CA3024155C (https=)
CY (1) CY1125465T1 (https=)
DK (1) DK3463328T3 (https=)
ES (1) ES2921230T3 (https=)
HR (1) HRP20220903T1 (https=)
HU (1) HUE059838T2 (https=)
IL (1) IL263372B2 (https=)
LT (1) LT3463328T (https=)
MX (1) MX390417B (https=)
NZ (1) NZ748721A (https=)
PL (1) PL3463328T3 (https=)
PT (1) PT3463328T (https=)
RS (1) RS63345B1 (https=)
RU (1) RU2765460C2 (https=)
SG (1) SG11201810123SA (https=)
SI (1) SI3463328T1 (https=)
SM (1) SMT202200471T1 (https=)
UA (1) UA122719C2 (https=)
WO (1) WO2017209865A1 (https=)
ZA (1) ZA201808360B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3119384T (pt) 2014-03-20 2018-12-12 Cymabay Therapeutics Inc Tratamento de doenças colestáticas intra-hepáticas
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
WO2020102337A1 (en) * 2018-11-16 2020-05-22 Cymabay Therapeutics, Inc. Combination treatment of nafld and nash
FI4225291T3 (fi) * 2021-02-01 2024-06-03 Cymabay Therapeutics Inc Kolangiopatioiden hoito seladelpaarilla
WO2024180642A1 (ja) 2023-02-28 2024-09-06 株式会社日立ハイテク プラズマ処理装置およびプラズマ処理装置の試料台の製造方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
AU5359496A (en) 1995-03-06 1996-09-23 Isis Pharmaceuticals, Inc. Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
ATE267207T1 (de) 1996-02-14 2004-06-15 Isis Pharmaceuticals Inc Kohlenhydratmodifizierte luckenhafte oligonukleotide
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US7981915B2 (en) 2003-04-30 2011-07-19 Beth Israel Deaconess Medical Center Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
EP1667964B1 (en) 2003-09-19 2009-07-22 Janssen Pharmaceutica N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
US7932268B2 (en) 2004-03-05 2011-04-26 The Trustees Of The University Of Pennsylvania Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
JP5694941B2 (ja) 2008-10-17 2015-04-01 シーマベイ セラピューティクス,インコーポレイティド 小型高密度ldl粒子を減少させる方法
NZ624963A (en) * 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
MA34097B1 (fr) 2010-03-30 2013-03-05 Novartis Ag Utilisations d'inhibiteurs de dgat1
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20160279085A1 (en) 2013-11-20 2016-09-29 Cymabay Therapeutics, Inc. Treatment of Severe Hyperlipidemia
HK1224186A1 (zh) 2013-11-20 2017-08-18 Cymabay Therapeutics, Inc. 纯阖家族型高胆固醇血症的治疗
PT3119384T (pt) 2014-03-20 2018-12-12 Cymabay Therapeutics Inc Tratamento de doenças colestáticas intra-hepáticas
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
BR112016023269A8 (pt) 2014-04-11 2021-06-29 Cymabay Therapeutics Inc uso de ácido (r)-2-(4-((2-etóxi-3-(4-(trifluormetil)fenóxi)propil)-tio)-2-metilfenóxi)-acético ou sal do mesmo na fabricação de um medicamento para tratar doença hepática gordurosa não alcoólica ou esteato-hepatite não alcoólica
EA201790091A1 (ru) 2014-06-26 2017-07-31 Саймабэй Терапьютикс, Инк. Лечение тяжелой гипертриглицеридемии
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
SMT202200171T1 (it) 2017-09-26 2022-05-12 Cymabay Therapeutics Inc Trattamento del prurito colestatico con seladelpar
CA3118965A1 (en) 2018-11-16 2020-05-22 Cymabay Therapeutics, Inc. Treatment of obesity and its complications
WO2020102337A1 (en) 2018-11-16 2020-05-22 Cymabay Therapeutics, Inc. Combination treatment of nafld and nash

Also Published As

Publication number Publication date
US20200061006A1 (en) 2020-02-27
BR112018074147A2 (pt) 2019-03-06
US10272058B2 (en) 2019-04-30
KR20190015363A (ko) 2019-02-13
EP3463328B1 (en) 2022-06-15
DK3463328T3 (da) 2022-07-04
CA3024155A1 (en) 2017-12-07
SI3463328T1 (sl) 2022-08-31
RU2018146504A3 (https=) 2020-07-27
MX2018014915A (es) 2019-04-24
KR102408288B1 (ko) 2022-06-10
IL263372A (en) 2018-12-31
JP7079735B2 (ja) 2022-06-02
US20210220305A1 (en) 2021-07-22
RS63345B1 (sr) 2022-07-29
AU2017274293B2 (en) 2022-03-31
US10478411B2 (en) 2019-11-19
RU2765460C2 (ru) 2022-01-31
WO2017209865A1 (en) 2017-12-07
CA3024155C (en) 2023-10-10
LT3463328T (lt) 2022-08-10
PT3463328T (pt) 2022-07-07
MX390417B (es) 2025-03-20
RU2018146504A (ru) 2020-07-09
SG11201810123SA (en) 2018-12-28
NZ748721A (en) 2022-04-29
SMT202200471T1 (it) 2023-01-13
CN109195594A (zh) 2019-01-11
AU2017274293A1 (en) 2018-12-13
PL3463328T3 (pl) 2022-10-03
JP2019518022A (ja) 2019-06-27
US20190255004A1 (en) 2019-08-22
ZA201808360B (en) 2020-02-26
US11000494B2 (en) 2021-05-11
CY1125465T1 (el) 2025-05-09
US20170340589A1 (en) 2017-11-30
US20210000774A1 (en) 2021-01-07
HUE059838T2 (hu) 2023-01-28
CN121466055A (zh) 2026-02-06
US11596614B2 (en) 2023-03-07
IL263372B2 (en) 2023-06-01
ES2921230T3 (es) 2022-08-22
EP3463328A1 (en) 2019-04-10
US10813895B2 (en) 2020-10-27
HRP20220903T1 (hr) 2022-10-14

Similar Documents

Publication Publication Date Title
US11406611B2 (en) Treatment of intrahepatic cholestatic diseases
US11596614B2 (en) Treatment of intrahepatic cholestatic diseases
US11224580B2 (en) Treatment of intrahepatic cholestatic diseases
HK1262698A1 (en) Seladelpar for the treatment of primary biliary cholangitis
HK1262698B (en) Seladelpar for the treatment of primary biliary cholangitis
HK1229212A1 (en) Treatment of intrahepatic cholestatic diseases
HK1229212B (en) Treatment of intrahepatic cholestatic diseases